Price Reductions for 2014 Main Cycle
Summary of 1 April 2014 Price Reductions for 2014 Main Cycle by Drug / Manner of Administration / Percentage Reduction:
|
Drug |
MOA |
Percentage Reduction |
|---|---|---|
|
Aciclovir |
Oral |
25.45% |
|
Alendronic acid |
Oral |
28.02% |
|
Amiodarone |
Oral |
14.55% |
|
Amisulpride |
Oral |
22.92% |
|
Amlodipine |
Oral |
31.35% |
|
Amoxycillin |
Oral |
15.37% |
|
Amoxycillin with clavulanic acid |
Oral |
14.14% |
|
Atenolol |
Oral |
14.66% |
|
Azithromycin |
Oral |
35.26% |
|
Bicalutamide |
Oral |
13.98% |
|
Bisoprolol |
Oral |
25.70% |
|
Carvedilol |
Oral |
20.90% |
|
Cefaclor |
Oral |
11.67% |
|
Cefalotin |
Injection |
14.71% |
|
Cefepime |
Injection |
20.45% |
|
Ceftriaxone |
Injection |
35.88% |
|
Cephalexin |
Oral |
12.07% |
|
Cephazolin |
Injection |
47.71% |
|
Ciprofloxacin |
Oral |
21.71% |
|
Citalopram |
Oral |
31.86% |
|
Clomipramine |
Oral |
10.84% |
|
Clopidogrel |
Oral |
43.70% |
|
Clopidogrel with aspirin |
Oral |
29.57% |
|
Clozapine |
Oral |
15.77% |
|
Cyproterone |
Oral |
15.02% |
|
Diazepam |
Oral |
10.52% |
|
Diclofenac |
Oral |
13.53% |
|
Docetaxel |
Injection |
89.96% |
|
Dothiepin |
Oral |
36.58% |
|
Doxorubicin |
Injection/intravesical |
19.40% |
|
Doxycycline |
Oral |
16.28% |
|
Enalapril |
Oral |
10.92% |
|
Epirubicin |
Injection/intravesical |
15.42% |
|
Escitalopram |
Oral |
36.81% |
|
Exemestane |
Oral |
15.01% |
|
Famciclovir |
Oral |
38.60% |
|
Felodipine |
Oral |
17.90% |
|
Fentanyl |
Transdermal |
22.69% |
|
Fluconazole |
Injection |
53.12% |
|
Fluconazole |
Oral |
18.04% |
|
Fludarabine |
Injection |
47.75% |
|
Fluoxetine |
Oral |
20.91% |
|
Flutamide |
Oral |
10.27% |
|
Fluvoxamine |
Oral |
11.57% |
|
Folinic acid |
Injection |
34.48% |
|
Fosinopril |
Oral |
10.96% |
|
Frusemide |
Injection |
10.01% |
|
Frusemide |
Oral |
15.37% |
|
Gabapentin |
Oral |
22.50% |
|
Galantamine |
Oral |
13.55% |
|
Gemcitabine |
Injection |
35.01% |
|
Gemfibrozil |
Oral |
10.87% |
|
Glucose |
Injection |
37.02% |
|
Granisetron |
Injection |
44.94% |
|
Granisetron |
Oral |
24.72% |
|
Hydrocortisone |
Rectal |
10.24% |
|
Hydroxocobalamin |
Injection |
20.95% |
|
Hypromellose |
Oral application |
14.06% |
|
Ipratropium |
Inhalation |
11.49% |
|
Irinotecan |
Injection |
20.28% |
|
Isosorbide mononitrate |
Oral |
10.06% |
|
Isotretinoin |
Oral |
11.27% |
|
Lactulose |
Oral |
16.24% |
|
Lamivudine |
Oral |
15.75% |
|
Lamotrigine |
Oral |
14.14% |
|
Lansoprazole |
Oral |
15.80% |
|
Latanoprost |
Application to the eye |
25.39% |
|
Leflunomide |
Oral |
15.54% |
|
Lercanidipine |
Oral |
18.37% |
|
Levetiracetam |
Oral |
21.87% |
|
Lisinopril |
Oral |
12.34% |
|
Meloxicam |
Oral |
27.43% |
|
Metformin |
Oral |
12.33% |
|
Methotrexate |
Injection |
18.20% |
|
Methylprednisolone |
Injection |
13.05% |
|
Metronidazole |
Injection |
45.05% |
|
Mirtazapine |
Oral |
27.54% |
|
Mitozantrone |
Injection |
23.17% |
|
Moclobemide |
Oral |
12.98% |
|
Mometasone |
Application |
11.13% |
|
Morphine |
Injection |
27.67% * |
|
Nifedipine |
Oral |
11.15% |
|
Norfloxacin |
Oral |
14.52% |
|
Omeprazole |
Oral |
20.74% |
|
Ondansetron |
Injection |
41.80% |
|
Ondansetron |
Oral |
42.39% |
|
Oxaliplatin |
Injection |
59.89% |
|
Oxybutynin |
Oral |
11.66% |
|
Paclitaxel |
Injection |
35.84% |
|
Pamidronic acid |
Injection |
12.98% |
|
Pantoprazole |
Oral |
33.83% |
|
Paroxetine |
Oral |
16.15% |
|
Perindopril |
Oral |
18.99% |
|
Perindopril with indapamide |
Oral |
17.98% |
|
Pindolol |
Oral |
10.89% |
|
Pioglitazone |
Oral |
26.03% |
|
Pravastatin |
Oral |
26.90% |
|
Prochlorperazine |
Oral |
19.72% |
|
Quinapril |
Oral |
10.59% |
|
Rabeprazole |
Oral |
38.96% |
|
Ramipril |
Oral |
17.36% |
|
Ranitidine |
Oral |
18.81% |
|
Risperidone |
Oral |
26.23% |
|
Salbutamol |
Inhalation |
10.44% |
|
Sertraline |
Oral |
33.35% |
|
Simvastatin |
Oral |
39.97% |
|
Sodium chloride |
Injection |
10.41% |
|
Sotalol |
Oral |
12.04% |
|
Sucralfate |
Oral |
10.03% |
|
Sumatriptan |
Oral |
23.46% |
|
Tamoxifen |
Oral |
15.79% |
|
Terbinafine |
Oral |
19.01% |
|
Ticlopidine |
Oral |
21.14% |
|
Topiramate |
Oral |
18.60% |
|
Topotecan |
Injection |
55.88% |
|
Tramadol |
Injection |
13.89% |
|
Tramadol |
Oral |
15.06% |
|
Valaciclovir |
Oral |
56.52% |
|
Valproic acid |
Oral |
20.50% |
|
Vancomycin |
Injection |
20.90% |
|
Vinorelbine |
Injection |
28.03% |
For further information about ex-manufacturer level weighted average disclosed prices for each brand, and confirmation of brands with no reductions, please see the legal determination on the Comlaw.com website.
Price reductions will apply to brands listed in Schedule 1 of the determination. Those in Schedule 2 of the determination will not take a price disclosure reduction as their percentage difference was below 10%. Any brands listed after 30 September 2013 for a pharmaceutical item that has a determination in Schedule 1 will also take the reduction on 1 April 2014.
Final prices applicable on 1 April 2014 will be available under the ‘Advance Notice of New Prices Resulting from EAPD Cycles’ link on this Web site from early March 2014.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEDT on Monday, 23 December 2013.
* This reduction was not applied because the 27.67% average difference from the previous prices occurred only as a result of a price increase during the data collection period. See amending legislative instrument PB 8 of 2014.
